Sandip Kapadia

Mr. Kapadia is Chief Financial Officer and has over 25 years of life sciences industry experience across multiple therapeutic areas and has provided strategic financial oversight and guidance to companies both in the United States and Europe. Most recently, he served as the Chief Financial Officer at Intercept, where he built upon the company’s key functional capabilities, developed and executed financial and capital strategies to prepare for commercial launch. Prior to Intercept, Mr. Kapadia spent the majority of his career at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands and the United Kingdom, where he held positions of varying levels of responsibility, including most recently serving as Chief Financial Officer of North America at Novartis’s generic division, Sandoz. He currently serves on the board of directors of Passage Bio, Inc., Molecular Partners AG and VectivBio Holding AG.

Mr. Kapadia has a bachelor’s degree in business administration and accounting from Montclair State University, an MBA from Rutgers Graduate School of Management, and is a Certified Public Accountant.